Myositis and myasteniform syndrome related to pembrolizumab

This case report concerns a 63-year-old man affected by metastatic undifferentiated liposarcoma. After receiving pembrolizumab as a second-line treatment in a clinical trial, the patient experienced an immune-mediated myocarditis, myositis and myasteniform syndrome. The last two adverse events showe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Case Rep
Egile Nagusiak: Sanchez-Sancho, Pablo, Selva-O'Callaghan, Albert, Trallero-Araguás, Ernesto, Ros, Javier, Montoro, Bruno
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2021
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8296758/
https://ncbi.nlm.nih.gov/pubmed/34290006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2021-241766
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak